生物科技公司Azenta（AZTA）今日盘中股价大跌5.66%，主要原因是公司公布的季度业绩不及市场预期。
根据Azenta公布的最新财报，截至3月31日的季度内，公司调整后每股收益为5美分，低于分析师平均预期的7美分。营收同比下降9.9%至1.4342亿美元，虽略高于分析师预期的1.4091亿美元，但仍显示出公司业务增长面临压力。更值得注意的是，公司本季度净亏损高达4,046万美元，每股亏损88美分。
这份疲软的财报进一步加剧了投资者对Azenta的担忧。数据显示，Azenta股价在本季度已下跌26.6%，今年迄今为止更是累计下跌49.2%。分析师对公司的平均评级为"持有"，其中包括2个"强烈买入"或"买入"评级，5个"持有"评级，以及1个"卖出"或"强烈卖出"评级。华尔街给予Azenta未来12个月的目标价中位数为45.00美元。鉴于公司持续疲软的业绩表现和股价走势，投资者可能需要密切关注Azenta未来的业务发展和转型策略。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.